Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IKK alpha/beta (pS180/181) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IKK alpha/beta (pS180/181) expression in HEK293T LPS-treated (A), Raw264.7 TNFa-treated (B), PC12 LPS-treated (C) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of BCL2 (pT69) staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of BCL2 (pT69) expression in HepG2 UV-treated (A), HeLa (B), HL60 (C), THP1 (D), Jurkat paclitaxel-treated (E), NIH3T3 H2O2-treated (F), PC12 H2O2-treated (G) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Beta-arrestin-1 (pS412) staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Beta-arrestin-1 (pS412) expression in HeLa (A), HEK293T (B), Raw264.7 (C), rat kidney (D) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of c-SRC (pY529) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of c-SRC (pY529) expression in K562 (A), HuvEc (B), Jurkat (C), COLO205 (D), HEK293T EGF-treated (E), A431 pervanadate-treated (F) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of ELK1 (pS389) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of ELK1 (pS389) expression in HT29 (A), HeLa (B), Jurkat (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of Calnexin staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Calnexin staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Calnexin expression in MCF7 (A), HeLa (B), MDAMB231 (C) whole cell lysates.)
Application Data (Direct ELISA antibody dose-response curve using Anti-TRK B (pY516) Antibody. Antigen (phosphopeptide and non-phosphopeptide) concentration is 5 ug/ml. Goat Anti-Rabbit IgG (H&L) - HRP was used as the secondary antibody, and signal was developed by TMB substrate.)
WB (Western Blot) (Western blot analysis of TRK B (pY516) expression in mouse kidney (A), rat kidney (B), BV2 (C), PC12 (D), SGC7901 (E) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of p47 phox (pS370) staining in THP1 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).)
WB (Western Blot) (Western blot analysis of p47 phox (pS370) expression in HeLa serum starvation-treated (A), THP1 (B), Raw264.7 serum starvation-treated (C), H9C2 serum starvation-treated (D) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of JAK2 (pY1007) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of JAK2 (pY1007) expression in HeLa (A), TF1 (B), NIH3T3 (C), rat kidney (D) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of AKT (pS473) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of AKT (pS473) expression in HeLa (A), SP2/0 (B), mouse heart (C), rat heart (D), rat liver (E) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of GRK2 (pS29) staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of GRK2 (pS29) expression in Ramos (A), THP1 (B), U937 (C), C6 (D) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using CK-1alpha (Phospho-Tyr294) antibody. Western blot analysis of extracts from HT-29 cells, treated with heat shock, using CK-1alpha (Phospho-Tyr294) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (P-peptide-+ Western blot analysis of extracts from HT-29 cells, treated with heat shock, using Vitamin D Receptor (Phospho-Ser208) antibody. Immunofluorescence analysis of A549 cells, using Vitamin D Receptor (Phospho-Ser208) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Hela cells (Lane 2) and Hepg2 cells (Lane 3), using GR (Phospho-Ser203) Antibody. The lane on the left is treated with synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from A549 cells, treated with dexamethason (10 nM, 1 hour), using GR (Phospho-Ser203) antibody.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-TBK-pS172 Antibody (AAA283616) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-Wee1-S123 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antobodies working concentration was 0.5ug per ml.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
DB (Dot Blot) (Dot blot analysis of anti-hp53-S315 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of anti-phospho-Sox2-pS246 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
IF (Immunofluorescence) (Fluorescent confocal image of SY5Y cells stained with phospho-Sox2- S246 antibody. SY5Y cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with AAA286283 phospho-Sox2- S246 primary antibody (1:200, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 5 min). Note the highly specific localization of the phospho-Sox2 immunosignal mainly to the nucleus.)
DB (Dot Blot) (Dot blot analysis of Phospho-HER2-pY1112 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cells,untreated or treated with EGF,100ng/ml?using phospho HER2-Y1112 (left) or HER2 antibody(right))
WB (Western Blot) (Western blot analysis of lysates from Hela cell line, untreated or treated with UV(2h), using Phospho-RB(S612) Antibody(upper) or Tubulin (lower).)
WB (Western Blot) (Western blot analysis of lysates from NIH/3T3 cell line, untreated or treated with UV(2h), using Phospho-RB(S612) Antibody(upper) or Tubulin (lower).)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma)
WB (Western Blot) (The anti-RB Pab is used in Western blot to detect RB in, from left to right, HL60, T47D, and SK-BR-3 tissue lysates.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-MEK1-pS222 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cell,untreated or treated with EGF?100ng/ml,using Phospho-MEK1-pS222(left) or MEK1-pS222 antibody(right).)
ICC (Immunocytochemistry) (Immunofluorescent analysis of Phosphorylation of H2A.X at Serine 139 in 3T3 or Hydroxyurea-treated 3T3 cells using Phospho-Histone H2A.X)
WB (Western Blot) (Western blot detection of Phosphorylation of H2A.X at Serine 139 in 3T3 or Hydroxyurea-treated 3T3 cell lysates using Phospho-Histone H2A.X (Ser139) mouse mAb (1:2000 diluted).Predicted band size:15KDa.Observed band size:15KDa.)
IHC (Immunohistochemisry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (The anti-Phospho-CDK1-S39 Pab is used in Western blot for detection in Ramos tissue lysate.)
DB (Dot Blot) (Dot blot analysis of anti-CDK11-S39 Phospho-specific Pab on nitrocellulose membrane. 50ng of nonphospho-peptide or phospho-peptide were adsorbed on their respective dots. Antibody working concentration was 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of CCNB1 Antibody (Phospho S35) Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of lysate from Hela cells(from left to right),untreated or treated with Nocodazole at 50ng/ml,using Phospho-CCNB1-S35 Antibody or CCNB1-S9 Antibody.Lysate at 15ug per lane.AAA290418 was diluted at 1:1100 dilution at each lane. A goat anti-rabbit IgG H&L (HRP) at 1:5000 dilution was used as the secondary antibody.)
WB (Western Blot) (Western blot analysis of extracts from C6 cells, untreated or treated with anisomycin (25 ug/ml), using Phospho-JNK/SAPK(Thr183/Tyr185) (upper) or GAPDH (lower).)
WB (Western Blot) (Western blot analysis of extracts from C6 cells, untreated or treated with anisomycin (25 ug/ml), using Phospho-JNK/SAPK(Thr183/Tyr185) (upper) or GAPDH (lower).)
IF (Immunofluorescence) (Confocal immunofluorescent analysis of Phospho-P53-S9 Antibody with A2058 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).)
WB (Western Blot) (Western blot analysis of Phospho-P53-S9 in HL60(left) and Ramos (right) cell line lysate.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-P53-S9 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antobodies working concentration was 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of anti-RASGRF1-pS929 Pab (RB14017) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of lysates from A431 cell line, untreated or treated with Forskolin(50uM, 30min), using Phospho-RASGRF1(S929) Antibody(upper) or Tubulin (lower).)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-p38 MAPK-T180 Antibody (Cat.# AP3642a) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of lysates from 293 cell line, untreated or treated with UV(2h), using Phospho-MAPK14(T180) Antibody(upper) or Tubulin (lower).)
WB (Western Blot) (Western blot analysis of extracts from HuvEc cells (Lane 2), using CRMP-2 (Phospho-Ser522) Antibody. The lane on the left is treated with antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide.
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human tonsil carcinoma tissue using VASP(Phospho-Ser239) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from serum-treated 293 and PMA-treated C6 cells using VASP(Phospho-Ser239) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ASK1(Phospho-Ser966) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from various cells using ASK1(Phospho-Ser966) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using 4E-BP1(Phospho-Thr45) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells using 4E-BP1(Phospho-Thr45) Antibody and the same antibody preincubated with blocking peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using IRS-1(Phospho-Ser636) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells untreated or treated with Insulin using IRS-1(Phospho-Ser636) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from HT29 cells, treated with CA or calf intestinal phosphatase (CIP), using IkappaB-beta (Phospho-Ser23) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using IkB-b(Phospho-Ser23) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using SHP-1(Phospho-Tyr536) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using SHP-1(Phospho-Tyr536) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from HL60 cells, treated with TNFa or calf intestinal phosphatase (CIP), using P38 MAPK (Phospho-Thr180) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using P38 MAPK(Phospho-Thr180) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HT29 cells untreated or treated with UV using P38 MAPK(Phospho-Thr180) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with IFNa or calf intestinal phosphatase (CIP), using STAT3 (Phospho-Ser727) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using STAT3(Phospho-Ser727) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using STAT3(Phospho-Ser727) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela and HepG2 cells untreated or treated with PMA usingSTAT3(Phospho-Ser727) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from COS7 cells, treated with starve or calf intestinal phosphatase (CIP), using Estrogen Receptor-alpha (Phospho-Ser118) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF cells using Estrogen Receptor-a(Phospho-Ser118) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Estrogen Receptor-a(Phospho-Ser118) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from MDA cells untreated or treated with Estradiol using Estrogen Receptor-a(Phospho-Ser118) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence analysis of HeLa cells, using ALK (Phospho-Tyr1604) antibody. The picture on the right is treated with the synthesized peptide.)
IHC (Immunohistochemisry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue, using ALK (Phospho-Tyr1604) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from cos-7 cells (Lane 2), using ALK (Phospho-Tyr1604) Antibody. The lane on the left is treated with synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells, using ALK (Phospho-Tyr1604) antibody. The lane on the right is treated with the synthesized peptide.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohistochemistry) (Immunohistochemical analysis ofparaffin-embedded human breast carcinomatissue using mTOR (Phospho-Ser2448) Antibody)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreatedor treated with PMA using mTOR(Phospho-Ser2448) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF cells using mTOR(Phospho-Ser2448) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using mTOR(Phospho-Ser2448) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treatedwith IFNa or calf intestinal phosphatase (CIP), using mTOR(Phospho-Ser2448) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human brain tissue using CRMP-2 (Phospho-Thr509) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from HT-29 cells treated with heat shock using CRMP-2 (Phospho-Thr509) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Cyclin C (Phospho-Ser275) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells (Lane 2), A549 cells (Lane 3) and Hela cells (Lane 4), using Cyclin C (Phospho-Ser275) Antibody. The lane on the left is treated with antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence analysis of HuvEc cells, using Kir6.2 (Phospho-Thr224) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from HeLa cells, using Kir6.2 (Phospho-Thr224) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (mmunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using 4E-BP1 (Phospho-Ser64) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells, treated with Insulin (0.01U/ml, 15mins), using 4E-BP1 (Phospho-Ser64) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.